Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

CD8β depletion does not prevent control of viral replication or protection from challenge in macaques chronically infected with a live attenuated simian immunodeficiency virus.

Sutton MS, Ellis-Connell A, Balgeman AJ, Barry G, Weiler AM, Hetzel SJ, Zhou Y, Lau-Kilby AW, Mason RD, Biris KK, Mascola JR, Sullivan NJ, Roederer M, Friedrich TC, O'Connor SL.

J Virol. 2019 May 15. pii: JVI.00537-19. doi: 10.1128/JVI.00537-19. [Epub ahead of print]

PMID:
31092584
2.

Amount and time exert independent influences on intertemporal choice.

Amasino DR, Sullivan NJ, Kranton RE, Huettel SA.

Nat Hum Behav. 2019 Apr;3(4):383-392. doi: 10.1038/s41562-019-0537-2. Epub 2019 Feb 25.

PMID:
30971787
3.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.

Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team.

Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.

PMID:
30686586
4.

Indulgent Foods Can Paradoxically Promote Disciplined Dietary Choices.

Sullivan NJ, Fitzsimons GJ, Platt ML, Huettel SA.

Psychol Sci. 2019 Feb;30(2):273-287. doi: 10.1177/0956797618817509. Epub 2019 Jan 9.

PMID:
30624140
5.

The Best Practice for Increasing Telephone Outreach: An Integrative Review.

Vergara FH, Sullivan NJ, Sheridan DJ, Davis JE.

Prof Case Manag. 2018 Nov/Dec;23(6):307-317. doi: 10.1097/NCM.0000000000000296.

PMID:
30289857
6.

Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction.

Cagigi A, Ploquin A, Niezold T, Zhou Y, Tsybovsky Y, Misasi J, Sullivan NJ.

J Infect Dis. 2018 Nov 22;218(suppl_5):S537-S544. doi: 10.1093/infdis/jiy450.

PMID:
30137549
7.

Ebola Immunity: Gaining a Winning Position in Lightning Chess.

Ploquin A, Zhou Y, Sullivan NJ.

J Immunol. 2018 Aug 1;201(3):833-842. doi: 10.4049/jimmunol.1700827. Review.

PMID:
30038036
8.

Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.

Cagigi A, Misasi J, Ploquin A, Stanley DA, Ambrozak D, Tsybovsky Y, Mason RD, Roederer M, Sullivan NJ.

J Infect Dis. 2018 Nov 22;218(suppl_5):S528-S536. doi: 10.1093/infdis/jiy333.

PMID:
30010811
9.

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo.

Mulangu S, Alfonso VH, Hoff NA, Doshi RH, Mulembakani P, Kisalu NK, Okitolonda-Wemakoy E, Kebela BI, Marcus H, Shiloach J, Phue JN, Wright LL, Muyembe-Tamfum JJ, Sullivan NJ, Rimoin AW.

J Infect Dis. 2018 Jan 30;217(4):529-537. doi: 10.1093/infdis/jix619.

10.

Functional interrogation and mining of natively paired human VH:VL antibody repertoires.

Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G.

Nat Biotechnol. 2018 Feb;36(2):152-155. doi: 10.1038/nbt.4052. Epub 2018 Jan 8.

11.

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.

Graham BS, Sullivan NJ.

Nat Immunol. 2018 Jan;19(1):20-28. doi: 10.1038/s41590-017-0007-9. Epub 2017 Dec 14. Review.

PMID:
29199281
12.

Improving Posthospital Discharge Telephone Reach Rates Through Prehospital Discharge Face-to-Face Meetings.

Vergara FH, Sheridan DJ, Sullivan NJ, Budhathoki C.

Prof Case Manag. 2017 Nov/Dec;22(6):275-283. doi: 10.1097/NCM.0000000000000243.

PMID:
29016418
13.

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, De Gregorio E, Barnett S, O'Hagan DT, Sullivan NJ, Koup RA, Seder RA, Loré K.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal2094. doi: 10.1126/scitranslmed.aal2094.

PMID:
28592561
14.

Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation.

Liu H, Dowdle JA, Khurshid S, Sullivan NJ, Bertos N, Rambani K, Mair M, Daniel P, Wheeler E, Tang X, Toth K, Lause M, Harrigan ME, Eiring K, Sullivan C, Sullivan MJ, Chang SW, Srivastava S, Conway JS, Kladney R, McElroy J, Bae S, Lu Y, Tofigh A, Saleh SMI, Fernandez SA, Parvin JD, Coppola V, Macrae ER, Majumder S, Shapiro CL, Yee LD, Ramaswamy B, Hallett M, Ostrowski MC, Park M, Chamberlin HM, Leone G.

Dev Cell. 2017 May 22;41(4):392-407.e6. doi: 10.1016/j.devcel.2017.04.024.

15.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ.

Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.

16.

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS.

Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.

17.

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, Shapiro CL, Chen CS.

Carcinogenesis. 2016 Apr;37(4):430-442. doi: 10.1093/carcin/bgw020. Epub 2016 Feb 19.

18.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B.

Lancet Infect Dis. 2016 Mar;16(3):311-20. doi: 10.1016/S1473-3099(15)00486-7. Epub 2015 Dec 23.

19.

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report.

Ledgerwood JE, Sullivan NJ, Graham BS.

N Engl J Med. 2015 Aug 20;373(8):776. doi: 10.1056/NEJMc1505499. No abstract available.

PMID:
26287857
20.

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.

Zhou Y, Sullivan NJ.

Curr Opin Immunol. 2015 Aug;35:131-6. doi: 10.1016/j.coi.2015.06.006. Epub 2015 Aug 3. Review.

PMID:
26247875
21.

Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS.

Neoplasia. 2015 Jun;17(6):497-508. doi: 10.1016/j.neo.2015.06.001.

22.

Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques.

Liang F, Ploquin A, Hernández JD, Fausther-Bovendo H, Lindgren G, Stanley D, Martinez AS, Brenchley JM, Koup RA, Loré K, Sullivan NJ.

J Immunol Methods. 2015 Oct;425:69-78. doi: 10.1016/j.jim.2015.06.011. Epub 2015 Jun 20.

23.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

24.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

25.

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.

Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE; RV 247 Study Team.

Lancet. 2015 Apr 18;385(9977):1545-54. doi: 10.1016/S0140-6736(14)62385-0. Epub 2014 Dec 23.

PMID:
25540891
26.

Simulation exercise to improve retention of cardiopulmonary resuscitation priorities for in-hospital cardiac arrests: A randomized controlled trial.

Sullivan NJ, Duval-Arnould J, Twilley M, Smith SP, Aksamit D, Boone-Guercio P, Jeffries PR, Hunt EA.

Resuscitation. 2015 Jan;86:6-13. doi: 10.1016/j.resuscitation.2014.10.021. Epub 2014 Nov 11.

PMID:
25447038
27.

Chimpanzee Adenovirus Vector Ebola Vaccine.

Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS; VRC 207 Study Team.

N Engl J Med. 2017 Mar 9;376(10):928-938. doi: 10.1056/NEJMoa1410863. Epub 2014 Nov 26.

28.

Camouflage and misdirection: the full-on assault of ebola virus disease.

Misasi J, Sullivan NJ.

Cell. 2014 Oct 23;159(3):477-86. doi: 10.1016/j.cell.2014.10.006. Epub 2014 Oct 16. Review.

29.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

30.

A new approach for monitoring ebolavirus in wild great apes.

Reed PE, Mulangu S, Cameron KN, Ondzie AU, Joly D, Bermejo M, Rouquet P, Fabozzi G, Bailey M, Shen Z, Keele BF, Hahn B, Karesh WB, Sullivan NJ.

PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3143. doi: 10.1371/journal.pntd.0003143. eCollection 2014 Sep.

31.

Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.

Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team.

J Infect Dis. 2015 Feb 15;211(4):549-57. doi: 10.1093/infdis/jiu511. Epub 2014 Sep 14.

32.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ.

Nat Med. 2014 Oct;20(10):1126-9. doi: 10.1038/nm.3702. Epub 2014 Sep 7.

PMID:
25194571
33.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2. Epub 2013 Nov 5.

34.

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2013 Jun;158(6):1425-32. doi: 10.1007/s00705-012-1594-2. Epub 2013 Jan 29. No abstract available.

35.

Ebolavirus vaccines for humans and apes.

Fausther-Bovendo H, Mulangu S, Sullivan NJ.

Curr Opin Virol. 2012 Jun;2(3):324-9. doi: 10.1016/j.coviro.2012.04.003. Epub 2012 May 4. Review.

36.

UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion.

Sullivan NJ, Tober KL, Burns EM, Schick JS, Riggenbach JA, Mace TA, Bill MA, Young GS, Oberyszyn TM, Lesinski GB.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):695-702. doi: 10.1038/jid.2011.329. Epub 2011 Oct 27.

37.

Comparative fitness of irradiated light brown apple moths (Lepidoptera: Tortricidae) in a wind tunnel, hedgerow, and vineyard.

Suckling DM, Stringer LD, Mitchell VJ, Sullivan TE, Sullivan NJ, Simmons GS, Barrington AM, El-Sayed AM.

J Econ Entomol. 2011 Aug;104(4):1301-8.

PMID:
21882696
38.

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.

Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ.

Nat Med. 2011 Aug 21;17(9):1128-31. doi: 10.1038/nm.2447.

PMID:
21857654
39.

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.

40.

Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway.

Fabozzi G, Nabel CS, Dolan MA, Sullivan NJ.

J Virol. 2011 Mar;85(6):2512-23. doi: 10.1128/JVI.01160-10. Epub 2011 Jan 12.

41.

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team.

Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.

PMID:
21034824
42.

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.

43.

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ.

PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.

44.

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.

Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ.

Virology. 2010 Jun 5;401(2):228-35. doi: 10.1016/j.virol.2010.02.029. Epub 2010 Mar 20.

45.

Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.

Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM.

Oncogene. 2009 Aug 20;28(33):2940-7. doi: 10.1038/onc.2009.180. Epub 2009 Jul 6.

46.

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Sullivan NJ, Martin JE, Graham BS, Nabel GJ.

Nat Rev Microbiol. 2009 May;7(5):393-400. doi: 10.1038/nrmicro2129. Review. Erratum in: Nat Rev Microbiol. 2009 Sep;7(9):684.

PMID:
19369954
47.

Immunopathology of highly virulent pathogens: insights from Ebola virus.

Zampieri CA, Sullivan NJ, Nabel GJ.

Nat Immunol. 2007 Nov;8(11):1159-64. Review.

PMID:
17952040
48.

Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.

Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM.

FASEB J. 2007 Nov;21(13):3763-70. Epub 2007 Jun 22.

PMID:
17586727
49.

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.

Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR.

PLoS Pathog. 2007 Jan;3(1):e9.

50.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS.

Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.

Supplemental Content

Loading ...
Support Center